恩华药业：全资子公司获三款抗精神病药大陆独家商业化权益

Core Viewpoint - Enhua Pharmaceutical's wholly-owned subsidiary, Enhua Hexin, has signed an exclusive commercial cooperation agreement with Green Leaf Pharmaceutical and Green Leaf Jiaao for the commercialization rights of three long-acting antipsychotic injections in mainland China, with a cooperation period until December 31, 2035 [1] Group 1 - Enhua Hexin will pay a one-time authorization fee of 20 million USD for the rights [1] - The agreement stipulates that Enhua Hexin must achieve a minimum sales target of 2.7 billion CNY from 2026 to 2035 [1] - If the sales target is met, Enhua Hexin will have priority negotiation rights two months after the agreement expires [1]